



Ferriprox[®] (deferiprone) – New formulation approval

- On May 21, 2020, [Chiesi Global Rare Diseases](#) announced the [FDA approval](#) of [Ferriprox \(deferiprone\)](#) twice-a-day 1000 mg oral tablets for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.
 - Approval is based on a reduction in serum ferritin levels. There are no controlled trials demonstrating a direct treatment benefit, such as improvement in disease-related symptoms, functioning, or increased survival.
 - Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with other chronic anemias.
- Ferriprox was previously approved as three times a day tablets.
- The approval for twice-a-day Ferriprox was supported by bioequivalence studies.
- Ferriprox carries a boxed warning for agranulocytosis and neutropenia.
- Additional warnings and precautions for Ferriprox include liver enzyme elevations, zinc deficiency, and embryo-fetal toxicity
- The most common adverse reactions ($\geq 5\%$) with Ferriprox use were nausea, vomiting and abdominal pain, alanine aminotransferase increased, arthralgia and neutropenia.
- The recommended starting dose of the new formulation of Ferriprox is 75 mg/kg/day (actual body weight) in two divided doses. The maximum oral dosage is 99 mg/kg/day (actual body weight) in two divided doses.
- Chiesi launch plans for Ferriprox are pending. Ferriprox will be available as a 1000 mg oral tablet with functional scoring.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.